Search results
Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief
Verywell Health via Yahoo News· 3 days agoBut after two pregnancies and the emergence of two new autoimmune conditions, my psoriasis became...
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 3 days agoDC from 19 to 21 May. J&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 4 days ago“We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice...
Alvotech (NYSE:ALVO) Releases Quarterly Earnings Results, Misses Estimates By $0.81 EPS
ETF DAILY NEWS· 12 hours agoAlvotech (NYSE:ALVO – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates ...
Amgen Inc. (NASDAQ:AMGN) Holdings Cut by Panagora Asset Management Inc.
ETF DAILY NEWS· 4 days agoPanagora Asset Management Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure ...
AbbVie Files Notice of Data Breach Impacting the Health Information of Tens of Thousands of...
JD Supra· 1 day agoOn May 22, 2024, AbbVie, Inc. filed a notice of data breach with the Attorney General of Texas after discovering that confidential information that had been entrusted to the company was subject ...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 4 days agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
InvestorPlace· 4 days agoFundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying...
Guselkumab Continues Winning Streak in Crohn's Disease
MedPage Today· 3 days agoInduction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy...
AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program
FierceBiotech· 3 days agoAltruBio has roared back after another pivot in its twisty history, securing up to $225 million in series B funding to take an immune checkpoint enhancer through a midphase ulcerative colitis ...